ADHD Medication Surge in Ontario Sparks Concerns Over Diagnosis Rates
Table of Contents
A dramatic 157% increase in stimulant prescriptions for attention deficit hyperactivity disorder (ADHD) in Ontario between 2015 and 2023 is raising questions about potential overdiagnosis and the appropriate use of medication, according to a new study. Published Thursday in JAMA Network Open, the research highlights a significant shift in treatment patterns, particularly among adult women, and points to factors like increased screen time and the rise of private assessment clinics as potential drivers.
Rising Prescriptions Mirror Pandemic Shifts
The study analyzed all stimulant medication prescriptions – including drugs like Ritalin and Adderall – dispensed across the province. Researchers found that while ADHD prescriptions were steadily increasing, the rate accelerated sharply in 2020, coinciding with the onset of the COVID-19 pandemic and associated lockdowns. Annual prescription increases jumped to 28% that year, a substantial increase from the 7% growth observed between 2015 and 2019.
Researchers from ICES, North York General Hospital, and the Hospital for Sick Children in Toronto suggest a confluence of factors may be at play. These include social and environmental changes, greater public awareness and acceptance of ADHD symptoms, and increased recognition of the condition in individuals who previously went undiagnosed.
Concerns Over Accuracy of Diagnosis
However, the study authors acknowledge a critical gap in data: the ability to definitively determine whether these medications are being prescribed appropriately. They caution that some individuals may be receiving inaccurate diagnoses – either being misdiagnosed with ADHD when another condition is present, or receiving a diagnosis when their symptoms are milder and don’t necessarily warrant medication.
“There’s a worry that some people may be unnecessarily exposed to the drug’s unwanted side effects and miss the opportunity to treat other mental disorders,” explained Dr. Daniel Myran, lead author of the study, a family and public health physician in Ottawa and a scientist at North York General Hospital.
Women Show the Most Significant Increase
The most striking increase in stimulant prescriptions was observed among adult women. Prescriptions for women aged 25-44 surged by approximately 421% over the study period, while those aged 18-24 increased by 369%. “Their growth is so rapid that by 2023, there were more women aged 25 to 44 who used a stimulant in the past year than men,” Dr. Myran noted.
This trend is partially attributed to a historical bias in diagnostic criteria, which traditionally focused on hyperactivity – a symptom more commonly observed in males. Increased attention is now being paid to the symptoms of inattention, such as difficulty focusing and prioritizing, which are often more prevalent in women. “It’s part of catching up,” Dr. Myran explained, “But the flip side is that it can also lead to overdiagnosis.”
Pediatric Prescriptions Also on the Rise
While the increase in adult diagnoses is more pronounced, the study also documented a significant rise in the number of children starting ADHD medication. Prescriptions for young girls aged 10-14 increased by 191%, outpacing the 67.5% increase seen in boys of the same age group. .
The Role of Virtual Care Clinics
The proliferation of private virtual care clinics offering ADHD assessments during the pandemic is also under scrutiny. While these clinics expanded access to diagnosis, researchers suggest they may have also contributed to diagnostic errors and overdiagnosis. Dr. Myran reported that patients were presenting to his family practice with diagnoses he deemed inaccurate, prompting him to initiate this research. “If you are misdiagnosed and given the wrong treatment, you may never get the right treatment for your condition,” he warned.
Attention medications can have side effects, including loss of appetite, trouble sleeping, and anxiety. Long-term effects may include increased blood pressure and a heightened risk of stroke and heart attack. While the benefit-risk balance is clear in cases of severe ADHD that interferes with education or employment, Dr. Myran expressed concern that prescriptions are increasingly being made to individuals for whom the risks may outweigh the benefits.
Broader Trends and Access to Care
Similar trends are being observed elsewhere. Heather Palis, a senior scientist at the British Columbia Center for Disease Control, conducted a parallel study in British Columbia this year, published in The Lancet, which revealed that diagnoses among women grew at more than double the rate of men during the pandemic. “This tells us that there is a population that needs services and treatment,” Dr. Palis stated, emphasizing the need to improve access to healthcare professionals who can accurately diagnose, prescribe medication, and monitor patients for side effects. “I think this really needs to be a first step in figuring out how to meet the service needs of people who have these new diagnoses and to include people who are at risk of being left behind.”
The Canadian Press’s health coverage is supported by a partnership with the Canadian Medical Association. The Canadian Press is solely responsible for this journalistic content.
